JP2015505295A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505295A5
JP2015505295A5 JP2014512088A JP2014512088A JP2015505295A5 JP 2015505295 A5 JP2015505295 A5 JP 2015505295A5 JP 2014512088 A JP2014512088 A JP 2014512088A JP 2014512088 A JP2014512088 A JP 2014512088A JP 2015505295 A5 JP2015505295 A5 JP 2015505295A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
article
container
dosage form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014512088A
Other languages
English (en)
Japanese (ja)
Other versions
JP6072778B2 (ja
JP2015505295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/039219 external-priority patent/WO2012162439A2/en
Publication of JP2015505295A publication Critical patent/JP2015505295A/ja
Publication of JP2015505295A5 publication Critical patent/JP2015505295A5/ja
Application granted granted Critical
Publication of JP6072778B2 publication Critical patent/JP6072778B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014512088A 2011-05-23 2012-05-23 フシジン酸を含む組成物およびそのためのパッケージ Active JP6072778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489017P 2011-05-23 2011-05-23
US61/489,017 2011-05-23
PCT/US2012/039219 WO2012162439A2 (en) 2011-05-23 2012-05-23 Compositions comprising fusidic acid and packages therefor

Publications (3)

Publication Number Publication Date
JP2015505295A JP2015505295A (ja) 2015-02-19
JP2015505295A5 true JP2015505295A5 (enExample) 2015-07-16
JP6072778B2 JP6072778B2 (ja) 2017-02-01

Family

ID=47218064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512088A Active JP6072778B2 (ja) 2011-05-23 2012-05-23 フシジン酸を含む組成物およびそのためのパッケージ

Country Status (3)

Country Link
US (4) US20140088062A1 (enExample)
JP (1) JP6072778B2 (enExample)
WO (1) WO2012162439A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300073A1 (en) * 1987-07-22 1989-01-25 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Use of fusidic acid in the treatment of aids-related complex and full-blown aids
US6103884A (en) * 1996-03-27 2000-08-15 The University Of Michigan Glycosylated analogs of fusidic acid
JPH11189547A (ja) * 1997-12-26 1999-07-13 Taisho Pharmaceut Co Ltd 安定化されたニコランジル製剤及びその製造方法
JP2005103148A (ja) * 2003-10-01 2005-04-21 Nisshin Kyorin Pharmaceutical Co Ltd ５−アミノサリチル酸の保存方法及び保存システム
EP1736156A4 (en) * 2004-04-15 2010-06-16 Eisai R&D Man Co Ltd COMPOSITION CONTAINING 4-AMINO-5-CHLORO-N-¬ (1R, 3R, 5S) -8-METHYL-8-AZABICYCLO-3.2.1 OCT-3-YL-2-β-methyl-2-ynyloxy BENZAMIDE STABILIZED
BRPI0513417A (pt) * 2004-07-16 2008-05-06 Cipla Ltd composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
US20060076536A1 (en) * 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
EP1977734A1 (en) * 2007-04-03 2008-10-08 Royal College of Surgeons in Ireland A method of producing fast dissolving tablets
CN100566704C (zh) * 2007-10-12 2009-12-09 西藏康欣药业有限公司 夫西地酸钠冻干粉针剂
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
SI2403480T1 (sl) * 2009-02-18 2013-07-31 Sulur, Vanangamudi Subramanian Postopek za izdelavo kreme na osnovi fusidne kisline
US20120035144A1 (en) * 2009-04-20 2012-02-09 Apex Laboratories Private Limited Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it.
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2010132695A5 (enExample)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2015078230A5 (enExample)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2012079092A3 (en) Testosterone undecanoate compositions
JP2013520405A5 (enExample)
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
JP2010222367A5 (enExample)
JP2016510019A5 (enExample)
WO2012035480A3 (en) Pharmaceutical compositions of curcumin
JP2012236834A5 (enExample)
JP2010520246A5 (enExample)
JP2014530801A5 (enExample)
JP2014205701A5 (enExample)
JP2013518051A5 (enExample)
ECSP13012399A (es) Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno
HK1203050A1 (en) Novel dosage and formulation
JP2018039810A5 (enExample)
PH12014500191A1 (en) Use of organic compound for the treatment of noonan syndrome
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
JP2016537364A5 (enExample)
JP2015521647A5 (enExample)
RU2014146562A (ru) Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий
JP2013510845A5 (enExample)